WuXi Biologics Financials

Market Capitalization HK$105.17 Billion as of July 1, 2025

Valuations Metrics as of Jul. 4, 2025

Trailing PE	30.35
Forward PE	25.05
Price to Sales TTM	HK$5.62
Price to Book MRQ	HK$2.53
Enterprise to Revenue	5.53
Enterprise to EBITDA	17.65

Financial Reports as of Dec. 31, 2024

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2024-12-31
Profit Margin	17.97%
Operating Margin	27.38%
Return on Assets TTM	5.05%
Return on Equity TTM	8.82%

Income Statement

Revenue TTM	HK$20,451,397,669
Revenue per Share TTM	HK$4.58
Quarterly Revenue Growth	18.30%
Gross Profit TTM	HK$8,378,413,087
EBITDA	HK$6,591,787,000
Net Income to Common TTM	HK$3,675,244,189
Diluted EPS TTM	HK$0.85
Quarterly Earnings Growth YoY	63.90%

Balance Sheet

Total Cash MRQ	HK$11,728,291,817
Total Cash per Share MRQ	HK$2.61
Total Debt MRQ	HK$
Total Debt to Equity MRQ	10.86
Current Ratio MRQ	2.73
Book Value per Share MRQ	HK$10.19

Cash Flow

Operating Cash Flow TTM	HK$5,713,418,096
Levered Free Cash Flow TTM	HK$-2,514,537,992

2269 Stock Info as of Jul. 4, 2025

Stock Statistics

Shares Outstanding	4,105,937,505
Float Shares	3,578,119,239
Avg 10 Volume	37,992,663
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	13.07%
% Held by Institutions	35.41%

Stock Price Summary

Beta	0.55
Fifty Two Week Low	HK$10.14
Fifty Two Week High	HK$29.30
Fifty Two Week Change	58.78%
Day 50 MA	HK$24.29
Day 200 MA	HK$20.29

Dividends and Splits

Forward Annual Dividend Rate	HK$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	HK$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date
Ex Dividend Date
Last Split Factor
Last Split Date	2020-11-16